Line 1: |
Line 1: |
| + | {{DISPLAYTITLE:Renal Table: Recurrent Genomic Alterations Detected by Chromosomal Microarray}} |
| + | |
| + | '''Table 1 - Recurrent Genomic Alterations in AML Detected by Chromosomal Microarray (Literature Review)'''. This is a comprehensive list of CNAs and CN-LOH detectable by CMA testing with strong diagnostic, prognostic and treatment implications in AML. Table derived from Xu et al., 2018 [PMID: 32434132] with permission from Cancer Genetics. |
| {| class="wikitable" | | {| class="wikitable" |
| | colspan="8" |'''WHO Classification''' | | | colspan="8" |'''WHO Classification''' |
Line 6: |
Line 9: |
| |'''Papillary RCC''' | | |'''Papillary RCC''' |
| | | |
− | '''Type 1''' | + | '''Type 1''' |
| |'''Papillary RCC''' | | |'''Papillary RCC''' |
| | | |
Line 20: |
Line 23: |
| |15-20% | | |15-20% |
| |15-20% | | |15-20% |
− | | colspan="2" |1-5% | + | | colspan="2" | 1-5% |
− | |5% | + | | 5% |
− | |5% | + | | 5% |
| |- | | |- |
| |'''Origin''' | | |'''Origin''' |
Line 41: |
Line 44: |
| |1p- (10%) [2; R] | | |1p- (10%) [2; R] |
| | | | | |
− | |1p- (25%) [2; R] | + | | 1p- (25%) [2; R] |
| | colspan="2" |1p- (30%) [3; R] | | | colspan="2" |1p- (30%) [3; R] |
| |'''-1''' (90%) '''[1; D]<sup>c</sup>''' | | |'''-1''' (90%) '''[1; D]<sup>c</sup>''' |
Line 96: |
Line 99: |
| |'''+7/+7,+7''' (84%) '''[1; D]<sup>c</sup>''' | | |'''+7/+7,+7''' (84%) '''[1; D]<sup>c</sup>''' |
| |'''+7''' (25%) '''[1; D]''' | | |'''+7''' (25%) '''[1; D]''' |
− | | colspan="2" |+7 (30%) [3; R] | + | | colspan="2" | +7 (30%) [3; R] |
| | | | | |
| | | | | |
Line 140: |
Line 143: |
| |<nowiki>+12 (52%) [2; R]</nowiki> | | |<nowiki>+12 (52%) [2; R]</nowiki> |
| |<nowiki>+12 (15%) [3; R]</nowiki> | | |<nowiki>+12 (15%) [3; R]</nowiki> |
− | | colspan="2" |+12 (35%) [3; R] | + | | colspan="2" | +12 (35%) [3; R] |
| | | | | |
| | | | | |
Line 164: |
Line 167: |
| | | | | |
| |<nowiki>-15 (15%) [3; R]</nowiki> | | |<nowiki>-15 (15%) [3; R]</nowiki> |
− | | colspan="2" |-15 (15%) [3; R] | + | | colspan="2" | -15 (15%) [3; R] |
| | | | | |
| | | | | |
Line 260: |
Line 263: |
| | colspan="8" |'''Mutations (SNVs, Indels) [level of evidence; clinical significance]''' | | | colspan="8" |'''Mutations (SNVs, Indels) [level of evidence; clinical significance]''' |
| |- | | |- |
− | |Mutated | + | | Mutated |
| | | |
| in >20% | | in >20% |
Line 270: |
Line 273: |
| | | | | |
| |- | | |- |
− | |Mutated | + | | Mutated |
| | | |
| in 10-20% | | in 10-20% |